Details for Patent: 6,515,117

« Back to Dashboard

Which drugs does patent 6,515,117 protect, and when does it expire?

Patent 6,515,117 protects BYDUREON, BYDUREON PEN, BYDUREON BCISE, QTERNMET XR, XIGDUO XR, FARXIGA, and QTERN, and is included in six NDAs.

Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and fourteen patent family members in forty-one countries.

Summary for Patent: 6,515,117

Title:	C-aryl glucoside SGLT2 inhibitors and method
Abstract:	An SGLT2 inhibiting compound is provided having the formula A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Inventor(s):	Bruce Ellsworth, William N. Washburn, Philip M. Sher, Gang Wu, Wei Meng
Assignee:	AstraZeneca AB
Application Number:	US10/151,436
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,515,117
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 6,515,117

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No	6,515,117*PED				Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No	6,515,117*PED				Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	6,515,117*PED				Y
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-001	May 2, 2019		DISCN	Yes	No	6,515,117*PED				Y
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-002	May 2, 2019		DISCN	Yes	No	6,515,117*PED				Y
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-003	May 2, 2019		DISCN	Yes	No	6,515,117*PED				Y
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-004	May 2, 2019		DISCN	Yes	No	6,515,117*PED				Y

International Family Members for US Patent 6,515,117

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1506211		C300585	Netherlands
European Patent Office	1506211		PA2013008	Lithuania
European Patent Office	1506211		122013000033	Germany
European Patent Office	1506211		C20130006 00074	Estonia
European Patent Office	1506211		92182	Luxembourg
European Patent Office	1506211		2013/013	Ireland
European Patent Office	1506211		CA 2013 00019	Denmark